Factor Xa (Coagulation Factor Xa)

Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.

Also Known As:

Networked: 1088 relevant articles (53 outcomes, 250 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Giugliano, Robert P: 35 articles (01/2022 - 10/2010)
2.	Berkowitz, Scott D: 34 articles (01/2022 - 02/2013)
3.	Mahaffey, Kenneth W: 34 articles (01/2022 - 02/2012)
4.	Patel, Manesh R: 34 articles (01/2022 - 02/2012)
5.	Becker, Richard C: 34 articles (10/2021 - 05/2002)
6.	Fox, Keith A A: 34 articles (10/2021 - 03/2005)
7.	Piccini, Jonathan P: 32 articles (01/2022 - 01/2013)
8.	Hankey, Graeme J: 32 articles (10/2021 - 01/2013)
9.	Halperin, Jonathan L: 31 articles (01/2022 - 01/2013)
10.	Ruff, Christian T: 31 articles (01/2022 - 10/2010)

Related Diseases

1.	Thrombosis (Thrombus) 12/04/2003 - "Inhibition of factor Xa has the potential to provide effective treatment for both venous and arterial thrombosis. " 08/15/1995 - "These results indicate that factor Xa is primarily responsible for the procoagulant activity of clots in vitro and suggest a potential molecular mechanism for the observed efficacy of inhibitors of factor Xa in preventing recurrent thrombosis after coronary thrombolysis." 01/01/2015 - "Efficacy studies included the measurement of thrombus formation, activated partial thromboplastin time, bleeding time, and anti-factor Xa activity; safety studies included the measurement of hemodynamic, hematologic and immunologic parameters. " 02/01/2004 - "After anti-factor Xa and IIa activity pharmacokinetic characterization in healthy volunteers, clinical studies first explored the doses and then confirmed thrombosis prevention effects in postoperative (general and hip or knee replacement surgery) settings as compared with placebo and active treatments. " 03/01/1994 - "In addition, if any of the TF activity observed in this study was derived from injured endothelial or myointimal cells during preparation of the everted vessel segments, the techniques described could serve as a useful model for studying TF-induced thrombosis and factor Xa formation on injured blood vessels, and for evaluating the anti-thrombotic properties of TF-inhibitors."
2.	Hemorrhage 01/01/2023 - "However, randomized controlled trials are lacking, and most data are from retrospective or single-arm prospective studies in bleeding associated with activated factor X inhibitors. " 04/01/2016 - "Monitoring of anti-factor Xa levels to guide prophylactic dosing is an option, although the utility of this lab test is limited, as target anti-Xa ranges for VTE prophylaxis have not been universally defined and trials have not shown a clear link between anti-factor Xa levels and bleeding or thrombotic events. " 09/01/2010 - "Some studies have demonstrated elevated anti-factor Xa levels are associated with an increased risk of hemorrhage. " 01/01/2005 - "Data from these trials, although preliminary and based on small numbers of patients, suggest that direct selective Factor Xa inhibition may provide effective anticoagulation, perhaps without excessive bleeding. " 06/01/2023 - "To characterize the burden of illness associated with oral factor Xa (FXa) inhibitor-related bleeding in the US Medicare population. "
3.	Venous Thromboembolism 01/01/2009 - "The results of 3 large randomized trials of activated factor X inhibitors, for the prevention of venous thromboembolism, recently became available. " 11/15/2003 - "Clinical trials with factor Xa inhibition in the prevention of postoperative venous thromboembolism." 01/01/2023 - "However, one developed new-onset venous thromboembolism (VTE) despite therapeutic anti-factor Xa levels. " 01/01/2022 - "Patients who developed venous thromboembolism had anti-factor Xa activities comparable to those who did not suffer from venous thromboembolism." 01/01/2022 - "We did not observe a difference of median (IQR) anti-factor Xa activity between patients without venous thromboembolism [peak 0.22 IU/mL (0.14-0.32); 12-h trough 0.1 IU/mL (<0.1-0.17), 24-h trough < 0.1 IU/mL (<0.1- <0.1)] vs. patients with venous thromboembolism [peak 0.33 IU/mL (0.14-0.34); 12-h trough 0.12 IU/mL (<0.1-0.26); 24-h trough < 0.1 IU/mL (<0.1-<0.1)]. "
4.	Atrial Fibrillation 05/01/2016 - "Data sources included renal subgroup analysis of the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE-AF) trial and other published studies. " 07/01/2014 - "Critique of Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation trial." 01/01/2016 - "(Effective aNticaoGulation with factor xA next Generation in Atrial Fibrillation [ENGAGE AF-TIMI 48]; NCT00781391)." 01/01/2013 - "ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation." 02/01/2012 - "Promise of factor Xa inhibition in atrial fibrillation."
5.	Embolism (Embolus) 09/01/2009 - "Indirect systemic and oral direct factor Xa and oral direct thrombin inhibitors are currently being developed for the prevention of embolism in patients with AF." 05/01/1987 - "One additional patient, who had been treated one year earlier with the low molecular weight heparin, again experienced embolism during treatment with only 1 X 5,000 anti factor Xa units per day. " 01/01/2022 - "In the NAVIGATE ESUS trial (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source), an MRI substudy was carried out at 87 sites in 15 countries. " 12/01/2021 - "Post hoc exploratory analysis of data from the New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs Aspirin to Prevent Embolism in ESUS (NAVIGATE ESUS) trial, a randomized, phase 3 clinical trial with enrollment from December 2014 to September 2017. " 01/01/2021 - "Subgroup analyses of the New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs Aspirin to Prevent Embolism in ESUS (NAVIGATE ESUS) international, double-blind, randomized, event-driven phase 3 clinical trial. "

Related Drugs and Biologics

1.	Anticoagulants
2.	Rivaroxaban
3.	Thrombin
4.	Heparin (Liquaemin)
5.	Enoxaparin (Lovenox)
6.	Vitamin K
7.	Warfarin (Coumadin)
8.	apixaban
9.	Antithrombins
10.	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)

Related Therapies and Procedures

1.	Therapeutics
2.	Orthopedic Procedures
3.	Knee Replacement Arthroplasty (Total Knee Replacement)
4.	Catheters
5.	Percutaneous Coronary Intervention